- Global Pharma News & Resources

Wugen to Present at the Upcoming Jefferies London Healthcare Conference

ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will present at 9:45 a.m. GMT (4:45 a.m. ET) on Thursday, November 17, 2022 at the upcoming Jefferies London Healthcare Conference.

About Wugen

Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta™ platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit


Elsie Yau, Stern Investor Relations, Inc.

Editor Details

  • Company:
    • Businesswire
Last Updated: 10-Nov-2022